Download FREE Report Sample
Download Free sampleThe global Micafungin Sodium for Injection market was valued at 342.33 Million USD in 2021 and will grow with a CAGR of 2.19% from 2021 to 2027, based on Research newly published report.
The prime objective of Micafungin Sodium for Injection Market is to provide the insights on the post COVID-19 impact which will help market players in this field evaluate their business approaches. Also, Micafungin Sodium for Injection Market covers market segmentation by major market verdors, types, applications/end users and geography(North America, East Asia, Europe, South Asia, Southeast Asia, Middle East, Africa, Oceania, South America).
Micafungin (trade name Mycamine) is an echinocandin antifungal drug used to treat and prevent invasive fungal infections including candidemia, abscesses and esophageal candidiasis. It inhibits the production of beta-1,3-glucan, an essential component of fungal cell walls. Micafungin is administered intravenously. It received final approval from the U.S. Food and Drug Administration on March 16, 2005, and gained approval in the European Union on April 25, 2008.In 2013, Japan was the largest consumption place, with a consumption market share nearly 35.40%. In 2017, North America is the largest consumption place with the consumption market share of 28.98%.
By Market Verdors:
By Types:
By Applications:
Key Indicators Analysed
Key Reasons to Purchase
Speak to our Custom Research Team and get the Custom Research in a budget
Custom ResearchFrequently Asked Questions ?
A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.
A license granted to multiple users.
A license granted to a single business site/establishment.
A license granted to all employees within organisation access to the product.
Upto Working 24 to 48 hrs
Upto 72 hrs max - Weekends and Public Holidays
Online Payments with PayPal and CCavenue
Wire Transfer/Bank Transfer
Hard Copy